SCHEMBL15345127

SCHEMBL15345127

Cc1ccc(-c2cnn(C)c2C)cc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.66
CREBBP Q92793 2/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
PRMT5 O14744 2/20 0.43
WDR77 Q9BQA1 2/20 0.43
BRD4 O60885 2/20 0.41
KDR P35968 1/20 0.41
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
PDE2A O00408 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 1/20 0.38
LRRK2 Q5S007 1/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
APOBEC3A P31941 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12651134 0.84 CYP11B2 (0.62) CYP11B2CREBBPNPC1RAB9APRMT5
SCHEMBL12175373 0.83 CREBBP (0.62) CYP11B2CREBBPNPC1RAB9ABRD4
SCHEMBL15341756 0.81 CYP11B2 (0.58) CYP11B2CREBBPRAB9APRMT5WDR77
SCHEMBL17806508 0.81 CYP11B2 (0.58) CYP11B2CREBBPNPC1RAB9APRMT5
SCHEMBL12926053 0.81 CYP11B2 (0.58) CYP11B2CREBBPNPC1RAB9AKDR
SCHEMBL23402230 0.80 CYP11B2 (0.45) CYP11B2CREBBPNPC1RAB9APRMT5
SCHEMBL31372601 0.80 CYP11B2 (1.00) CYP11B2CREBBPPRMT5WDR77ALDH1A1
SCHEMBL12304102 0.79 CYP11B2 (0.44) CYP11B2CREBBPNPC1RAB9APRMT5
SCHEMBL25099090 0.78 CYP11B2 (0.55) CYP11B2CREBBPNPC1RAB9ABRD4
SCHEMBL15344206 0.77 RAB9A (0.51) CYP11B2CREBBPNPC1RAB9APRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP11B2 1605/4885CREBBP 6/4885NPC1 403/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP11B2 1605/4885CREBBP 6/4885NPC1 403/4885
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP11B2 19/4885CREBBP 401/4885NPC1 6/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP11B2 19/4885CREBBP 401/4885NPC1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.